Pulmonary embolism treatment approach
|
Pulmonary Embolism Microchapters |
|
Diagnosis |
|---|
|
Pulmonary Embolism Assessment of Probability of Subsequent VTE and Risk Scores |
|
Treatment |
|
Follow-Up |
|
Special Scenario |
|
Trials |
|
Case Studies |
|
Pulmonary embolism treatment approach On the Web |
|
Directions to Hospitals Treating Pulmonary embolism treatment approach |
|
Risk calculators and risk factors for Pulmonary embolism treatment approach |
Editor(s)-In-Chief: C. Michael Gibson, M.S., M.D. [1], The APEX Trial Investigators; Associate Editor(s)-In-Chief: Kashish Goel, M.D.
Overview
Prompt recognition, diagnosis and treatment of pulmonary embolism is critical. Anticoagulant therapy is the mainstay of treatment for patients who are hemodynamically stable. If hemodynamic compromise is present, then fibrinolytic therapy is recommended.
Step 1: Confirm PE
| Assess the pretest probability of PE by using one of the risk score: - Wells score - Geneva score - PERC | |||||||||||||||||||||||||||||||||
| Low pretest probability of PE (Wells score ≤ 4) | High pretest probability of PE (Wells score) > 4 OR Presence of shock OR Presence of hypotension | ||||||||||||||||||||||||||||||||
| Order D-dimer | |||||||||||||||||||||||||||||||||
| Normal D-dimer (<500 ng/ml) | Elevated D-dimer (>500 ng/ml) | Order CT pulmonary angiography | |||||||||||||||||||||||||||||||
| PE is excluded | Negative | Positive | |||||||||||||||||||||||||||||||
| PE is excluded | PE is confirmed | ||||||||||||||||||||||||||||||||
Step 2: Initial Treatment
Shown below is an algorithm depicting the initial management of pulmonary embolism.[1]
| Assess the severity of pulmonary embolism | |||||||||||||||||||||||||||||||||||||||||||||||||
| High-risk PE (also know as massive PE) Cardiogenic shock OR Persistent hypotension (≤90mmHg) OR Drop of the blood pressure by ≥ 40mmHg for > 15 min[2] OR ,br> Pulselessness OR Profound bradycardia (<40 bpm) with findings of shock | Intermediate-risk PE (also know as submassive PE) Right ventricular dysfunction AND/OR Myocardial injury (Troponin +) | Low-risk PE (also know as non-massive PE) No cardiogenic shock AND No hypotension AND No right ventricular dysfunction AND No myocardial injury (Troponin -) | |||||||||||||||||||||||||||||||||||||||||||||||
| Provide hemodynamic and respiratory support Begin high dose unfractionated heparin
Administer rapidly 500-1000 mL of normal saline | |||||||||||||||||||||||||||||||||||||||||||||||||
| Is there any contraindication for fibrinolytic therapy? | Is there any contraindication for anticoagulation therapy? | Is there any contraindication for anticoagulation therapy? | |||||||||||||||||||||||||||||||||||||||||||||||
| NO | YES | NO | YES | NO | YES | ||||||||||||||||||||||||||||||||||||||||||||
| Discontinue unfractionated heparin AND Begin fibrinolytic therapy | Surgical pulmonary embolectomy OR Percutaneous catheter embolectomy | Anticoagulation therapy AND Hospital admission | IVC filter AND Hospital admission | Anticoagulation therapy AND Early discharge/home treatment | IVC filter AND Early discharge/home treatment | ||||||||||||||||||||||||||||||||||||||||||||
| Does the patient fail to improve OR Develop cardiogenic shock? OR Develop hypotension? | Does the patient fail to improve OR Develop cardiogenic shock? OR Develop hypotension? | ||||||||||||||||||||||||||||||||||||||||||||||||
| YES | NO | YES | NO | ||||||||||||||||||||||||||||||||||||||||||||||
| Surgical pulmonary embolectomy OR Percutaneous catheter embolectomy | Continue with the same treatment | Is there any contraindication for fibrinolytic therapy? | Continue with the same treatment | ||||||||||||||||||||||||||||||||||||||||||||||
| NO | YES | ||||||||||||||||||||||||||||||||||||||||||||||||
| Hold anticoagulation and give thrombolytics | Surgical pulmonary embolectomy OR Percutaneous catheter embolectomy | ||||||||||||||||||||||||||||||||||||||||||||||||
| Does the patient fail to improve? | |||||||||||||||||||||||||||||||||||||||||||||||||
| YES | NO | ||||||||||||||||||||||||||||||||||||||||||||||||
| Surgical pulmonary embolectomy OR Percutaneous catheter embolectomy | Continue with the same treatment | ||||||||||||||||||||||||||||||||||||||||||||||||
Anticoagulation
The most common cause of mortality in patients with a pulmonary embolism, is a recurrent PE occurring within a few hours of the initial event.[3] Anticoagulation prevents further clot formation and extension, therefore it should be started as early as possible. Anticoagulation does not disaggregate existing clot, but it does facilitate the action of the body's endogenous lytic system. Anticoagulation is the cornerstone of therapy in an acute pulmonary embolism.[3][4] After initial risk stratification. Certain conditions like pericardial tamponade and aortic dissection can mimic pulmonary embolism. The use of anticoagulants is contraindicated in these medical conditions. Proceed with caution if these conditions are high on the differential. Immediate treatment should be initiated based on the following guidelines: [5][6][1]
- Initial treatment with parenteral anticoagulants, including subcutaneous low molecular weight heparin (such as enoxaparin and dalteparin), subcutaneous fondaparinux, or intravenous unfractionated heparin, should be administered unless contraindicated.
- ACCP guidelines[5] recommend low molecular weight heparin or fondaparinux instead of intravenous unfractionated heparin.
- If there is moderate-to-high clinical suspicion of a PE, anticoagulation should be initiated while awaiting confirmatory tests.
- Vitamin K antagonists such as warfarin should be started the same day. Parenteral anticoagulation should be continued for at least 5 days, and preferably until INR is 2.0 or above for 1-2 days.
- Warfarin therapy often requires frequent dose adjustment and monitoring of the INR. In PE, the INR goal should be between 2.0 and 3.0.
- In patients with suspected or confirmed heparin-induced thrombocytopenia, lepirudin or argatroban should be used.
Thrombolysis
- Unless previously contraindicated, thrombolysis is indicated in patients with a massive PE or those with a submassive PE who develop or are at risk of developing hypotension (SBP < 90 mmHg).
- Administration of a fibrinolytic via a peripheral intravenous catheter is recommended.
- FDA recommends a 100 mg dose of alteplase administered as a continuous infusion over 2 hours. This treatment is supported by AHA[6] and ACCP guidelines.[5]
- Withhold anticoagulation during the 2 hours of fibrinolytic infusion.
- The role of thrombolysis in a submassive PE is not established at this point.[7] Two ongoing trials are investigating the efficacy and safety of this approach.
- No large clinical trial has demonstrated a mortality benefit of thrombolytic therapy. However, it helps by accelerating clot lysis, improving pulmonary perfusion, and improving right ventricular function.[8][9]
To read more about dosage, contraindications, and guidelines, click here.
Surgical Procedures
- Catheter-assisted thrombus removal is recommended in patients with a massive PE who have contraindications to thrombolytic therapy or have failed thrombolysis.
- Thrombectomy is also recommended for patients who are in severe shock that may cause the patient to die before thrombolysis takes effect (hours).
- Pulmonary embolectomy is also recommended if a patient with the above conditions fails catheter-assisted embolectomy.
IVC Filter
- An IVC filter is indicated for patients for whom anticoagulation is contraindicated.
- Anticoagulation should be restarted once the contraindication is resolved.
Step 3: Long Term Treatment
- After treatment in the hospital, the patient should continue anticoagulation treatment for 3 months if the PE is provoked by surgery or a nonsurgical transient risk factor.
- An abnormal D-dimer level at the end of the treatment course might signal the need for continued treatment with anticoagulation for a first time unprovoked pulmonary embolus.[10]
- Long-term treatment is usually recommended with vitamin K antagonists like warfarin, unless contraindicated or some special circumstances.
- The recommended therapeutic INR range for patients with PE is 2.0-3.0.
- Continued warfarin administration needs close monitoring. The patient should have an appointment with the "anticoagulation clinic" before leaving the hospital.
Extended Anticoagulation
Extended Treatment means extending the anticoagulation therapy beyond the first 3 months. It is recommended in the following scenarios:
- For a pulmonary embolism that is unprovoked. The patient's risk should be re-evaluated at 3 months to consider whether or not extended therapy is warranted.
- Active cancer.
- Recurrent venous thromboembolism.
- Chronic thrombembolic pulmonary hypertension.
Salient Features:
- For extended therapy, the continued need for anticoagulation and the risk-benefit ratio should be re-evaluated at periodic intervals (eg, annually).
- Patients with recurrent thromboembolic disease, with or without anticoagulation, should be evaluated for possible thrombophilias.
Specific Circumstances
- Malignancy: Low molecular weight heparin is favored over warfarin based on the results of the CLOT trial.[11]
- Pregnancy: Low molecular weight heparin is preferred to avoid the known teratogenic effects of warfarin.
- Asymptomatic patients who are diagnosed with an incidental PE should be managed with the same criteria as those with symptomatic PE.
Newer Anticoagulants
- Dabigatran (direct thrombin inhibitor), Rivaroxaban (Factor Xa inhibitor), and other drugs in the same classes, provide an alternate option to warfarin/LMWH for treatment of PE.
- Advantages include the availability of an oral formulation, no frequent monitoring requirement, a predictable effect profile, and few (known) drug interactions.
- Disadvantages include the currently limited prospective trial data, the theoretical interaction with statins (as they are metabolized by the same CYP3A4 enzyme), and the risk of bleeding.
2008 ESC Guidelines Treatment High-risk Pulmonary Embolism (DO NOT EDIT)[1]
| Class I |
| "1. Anticoagulation with unfractionated heparin should be initiated without delay in patients with high-risk PE. (Level of Evidence: A) " |
| "2. Systemic hypotension should be corrected to prevent progression of RV failure and death due to PE. (Level of Evidence: C)" |
| "3. Vasopressive drugs are recommended for hypotensive patients with PE. (Level of Evidence: C)" |
| "4. Oxygen should be administered in patients with hypoxaemia.(Level of Evidence: C)" |
| "5. Thrombolytic therapy should be used in patients with high-risk PE presenting with cardiogenic shock and/or persistent arterial hypotension.(Level of Evidence: A)" |
| "6. Surgical pulmonary embolectomy is a recommended therapeutic alternative in patients with high-risk PE in whom thrombolysis is absolutely contraindicated or has failed.(Level of Evidence: C)" |
| Class III |
| "1. Aggressive fluid challenge is not recommended. (Level of Evidence: B)" |
| Class IIa |
| "1. Dobutamine and dopamine may be used in patients with PE, low cardiac output and normal blood pressure. (Level of Evidence: B)" |
| Class IIb |
| "1.Catheter embolectomy or fragmentation of proximal pulmonary arterial clots may be considered as an alternative to surgical treatment in high-risk patients when thrombolysis is absolutely contraindicated or has failed. (Level of Evidence: C)" |
2008 ESC Guidelines Treatment Non-high-risk Pulmonary Embolism (DO NOT EDIT)[1]
| Class I |
| "1. Anticoagulation should be initiated without delay in patients with high or intermediate clinical probability of PE while diagnostic workup is still ongoing. (Level of Evidence: C)" |
| "2. Use of LMWH or fondaparinux is the recommended form of initial treatment for most patients with non-high-risk PE. (Level of Evidence: A) " |
| "3. In patients at high risk of bleeding and in those with severe renal dysfunction, unfractionated heparin with an aPTT target range of 1.5–2.5 times normal is a recommended form of initial treatment. (Level of Evidence: C) " |
| "4. Initial treatment with unfractionated heparin, LMWH or fondaparinux should be continued for at least 5 days and (Level of Evidence: A) may be replaced by vitamin K antagonists only after achieving target INR levels for at least 2 consecutive days (Level of Evidence: C)" |
| Class III |
| "1. Thrombolytic therapy should be not used in patients with low-risk PE (Level of Evidence: B) " |
| Class IIb |
| "1. Routine use of thrombolysis in non–high-risk PE patients is not recommended, but it may be considered in selected patients with intermediate-risk PE (Level of Evidence: B) " |
ESC 2008 Guidelines Recommendations Long-term treatment (DO NOT EDIT)[1]
| Class I |
| "1. For patients with PE secondary to a transient (reversible) risk factor, treatment with a VKA is recommended for 3 months.(Level of Evidence: A)" |
| "2. For patients with unprovoked PE, treatment with a VKA is recommended for at least 3 months. (Level of Evidence: A)" |
| "3. For patients with a second episode of unprovoked PE, long-term treatment is recommended. (Level of Evidence: A)" |
| "4. In patients who receive long-term anticoagulant treatment, the risk/benefit ratio of continuing such treatment should be reassessed at regular intervals. (Level of Evidence: C)" |
| "5. In patients with PE, the dose of VKA should be adjusted to maintain a target INR of 2.5 (range 2.0–3.0) regardless of treatment duration.(Level of Evidence: A)" |
| Class IIb |
| "1. Patients with a first episode of unprovoked PE and low risk of bleeding, and in whom stable anticoagulation can be achieved, may be considered for long-term oral anticoagulation. (Level of Evidence: B)" |
| Class IIa |
| "1. For patients with PE and cancer, LMWH should be considered for the first 3–6 months (Level of Evidence: B) after this period, anticoagulant therapy with VKA or LMWH should be continued indefinitely or until the cancer is considered cured.(Class I,Level of Evidence: C)" |
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P; et al. (2008). "Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)". Eur Heart J. 29 (18): 2276–315. doi:10.1093/eurheartj/ehn310. PMID 18757870.
- ↑ 2.0 2.1 Kucher N, Goldhaber SZ (2005). "Management of massive pulmonary embolism". Circulation. 112 (2): e28–32. doi:10.1161/CIRCULATIONAHA.105.551374. PMID 16009801.
- ↑ 3.0 3.1 Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Schwartz JS, Thompson BT, Popovich J, Hobbins TE (1992). "The clinical course of pulmonary embolism". N. Engl. J. Med. 326 (19): 1240–5. doi:10.1056/NEJM199205073261902. PMID 1560799. Retrieved 2011-12-12. Unknown parameter
|month=ignored (help) - ↑ Goldhaber SZ, Visani L, De Rosa M (1999). "Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)". Lancet. 353 (9162): 1386–9. PMID 10227218. Retrieved 2011-12-12. Unknown parameter
|month=ignored (help) - ↑ 5.0 5.1 5.2 Kearon C, Akl EA, Comerota AJ; et al. (2012). "Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e419S–94S. doi:10.1378/chest.11-2301. PMID 22315268. Unknown parameter
|month=ignored (help) - ↑ 6.0 6.1 Jaff MR, McMurtry MS, Archer SL; et al. (2011). "Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association". Circulation. 123 (16): 1788–830. doi:10.1161/CIR.0b013e318214914f. PMID 21422387. Unknown parameter
|month=ignored (help) - ↑ Dong B, Jirong Y, Liu G, Wang Q, Wu T. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev 2006;(2):CD004437. PMID 16625603.
- ↑ Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W (2002). "Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism". N. Engl. J. Med. 347 (15): 1143–50. doi:10.1056/NEJMoa021274. PMID 12374874. Retrieved 2011-12-13. Unknown parameter
|month=ignored (help) - ↑ Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M (1990). "A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism". Chest. 98 (6): 1473–9. PMID 2123152. Retrieved 2011-12-21. Unknown parameter
|month=ignored (help) - ↑ Palareti G, Cosmi B, Legnani C; et al. (2006). "D-dimer testing to determine the duration of anticoagulation therapy". N. Engl. J. Med. 355 (17): 1780–9. doi:10.1056/NEJMoa054444. PMID 17065639.
- ↑ Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). "Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer". N Engl J Med. 349 (2): 146–53. PMID 12853587.